These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2979064)

  • 21. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
    Pimm MV
    Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
    Jones RJ; Twelves CJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riboflavin and cancer: a review.
    Rivlin RS
    Cancer Res; 1973 Sep; 33(9):1977-86. PubMed ID: 4579772
    [No Abstract]   [Full Text] [Related]  

  • 26. [Targeting of antitumor drugs with monoclonal antibodies].
    Monneret C; Florent JC
    Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
    Pietersz GA; Kanellos J; McKenzie IF
    Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
    Villela LR; Stanford BL; Shah SR
    Pharmacotherapy; 2006 May; 26(5):641-54. PubMed ID: 16637794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Further research on the oncostatic action of a chemotherapeutic agent with anti-folic mechanism (trimethoprim-sulfamethoxazole)].
    La Pesa M; Curci E; Semeraro N; Mancini L
    Pathologica; 1973; 65(949):391-2. PubMed ID: 4597263
    [No Abstract]   [Full Text] [Related]  

  • 30. Toxicity and anticancer activity of a new triazine antifolate (NSC 127755).
    Corbett TH; Leopold WR; Dykes DJ; Roberts BJ; Griswold DP; Schabel FM
    Cancer Res; 1982 May; 42(5):1707-15. PubMed ID: 7066891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Some considerations of folic acid antagonists.
    Scott CW
    Ala J Med Sci; 1971 Jan; 8(1):99-106. PubMed ID: 5578506
    [No Abstract]   [Full Text] [Related]  

  • 32. The impact of p53 status on cellular sensitivity to antifolate drugs.
    Lu X; Errington J; Curtin NJ; Lunec J; Newell DR
    Clin Cancer Res; 2001 Jul; 7(7):2114-23. PubMed ID: 11448931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
    Müller C; Schubiger PA; Schibli R
    Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
    Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
    Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system.
    Hawkins GA; McCabe RP; Kim CH; Subramanian R; Bredehorst R; McCullers GA; Vogel CW; Hanna MG; Pomato N
    Cancer Res; 1993 May; 53(10 Suppl):2368-73. PubMed ID: 8485723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
    Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
    Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
    Fulton RJ; Uhr JW; Vitetta ES
    J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
    Calvert H
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
    [No Abstract]   [Full Text] [Related]  

  • 40. [Current state of chemosensitivity testing of tumors].
    Kaufmann M; Kubli F
    Dtsch Med Wochenschr; 1983 Jan; 108(4):150-4. PubMed ID: 6825592
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.